MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.6 USD | -0.62% |
|
+0.59% | +18.84% |
| 08:12pm | AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement | MT |
| 07:56pm | AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement | MT |
Presentation Operator MessageOperator (Operator)Welcome to the Merck & Company Q3 Sales and Ea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
130.4
USD
Average target price
141.6
USD
Spread / Average Target
+8.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.84% | 330B | |
| +33.38% | 700B | |
| -4.83% | 358B | |
| +3.39% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +5.83% | 161B | |
| -1.98% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc., Q3 2023 Earnings Call, Oct 26, 2023